Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05826457 · ClinicalTrials.gov registry record

North American Prodromal Synucleinopathy Consortium Stage 2

A clinical trial of Parkinson Disease and Multiple System Atrophy, sponsored by Washington University School of Medicine.

Recruiting
Registry status
500
Enrollment target
9
Study locations

NCT05826457 is a study of Parkinson Disease and Multiple System Atrophy that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 500 participants, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (91% lower). The trial reports 9 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05826457, a study of Parkinson Disease and Multiple System Atrophy, is actively recruiting participants, sponsored by Washington University School of Medicine.

RECRUITING
Registry status
500 participants
Enrollment target
9
Study locations

Study Summary

This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.

Study Locations (9)

California

  • University of California Los Angeles - Los Angeles
  • Stanford University - Redwood City

Minnesota

  • University of Minnesota - Minneapolis
  • Mayo Clinic Rochester - Rochester

Georgia

  • Emory University - Atlanta

Massachusetts

  • Massachusetts General Hospital - Boston

Missouri

  • Washington University School of Medicine - St Louis

Oregon

  • Oregon Health Sciences University - Portland

Quebec

  • McGill University Health Centre Research Institute - Montreal

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2022-08-12
Est. Completion 2025-05-01

What the Registry Record Tells You About NCT05826457

The ClinicalTrials.gov registry entry for NCT05826457 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (91% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 0 interventions.

NCT05826457 reports 9 study locations spanning 7 distinct geographic areas - top geographies include California, Minnesota, Georgia.

Frequently Asked Questions

What is clinical trial NCT05826457 about?

NCT05826457 is a clinical study titled "North American Prodromal Synucleinopathy Consortium Stage 2". This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.

What is the current status of trial NCT05826457?

This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2022-08-12. Estimated completion is 2025-05-01.

What conditions does trial NCT05826457 study?

This clinical trial studies the following conditions: Parkinson Disease, Multiple System Atrophy, Dementia With Lewy Bodies, REM Sleep Behavior Disorder, Lewy Body Dementia.

Who is sponsoring clinical trial NCT05826457?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05826457 being conducted?

This trial has 9 study locations across California, Georgia, Massachusetts, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.